CA 125 ANTIGEN  Serum

CA125

CA 125 Antigen

Gold Top Tube

24 hours

The concentration of CA 125 in a given specimen, as determined by assays from different manufacturers, can vary due to differences in assay methods and reagent specificity. The results reported by the laboratory to the physician must include the identity of the assay for CA 125 used. Values obtained with different assay methods cannot be used interchangeably. If, in the course of monitoring a patient, the assay method used for determining serial levels of CA 125 is changed, the laboratory must perform UCSF Clinical Labs Chemistry Page 2 of 2 Proc/Centaur/CA 125 additional testing to confirm baseline values. The ADVIA Centaur CA 125 II assay is based on the OC 125 and M11 antibodies available through agreement with Fujirebio Diagnostic, Inc. Assays using antibodies other than OC 125 and M11 may give different results.

In vitro diagnostic immunoassay test for the quantitative determination of CA 125 in human serum and to aid in the management of patients with ovarian carcinoma. The test is intended for use as an aid in monitoring patients previously treated for ovarian cancer. Serial testing for CA 125 in the serum of patients who are clinically free of disease should be used in conjunction with other clinical methods used for the early detection of cancer recurrence. The test is also intended for use as an aid in the management of ovarian cancer patients with metastatic disease by monitoring the progression or regression of disease in response to treatment. It is recommended that the ADVIA Centaur CA 125 II assay be used under the order of a physician trained and experienced in the management of gynecological cancers. This assay is not intended for screening or diagnosis of ovarian cancer or for use on any other system.